U.S. HSV1 Treatment Market – Industry Trends and Forecast to 2030

U.S. HSV1 Treatment Market Analysis and Size

Every year, the CDC reports an estimated 572,000 cases of genital herpes infections caused by the herpes simplex virus in the United States. Furthermore, individuals with HSV II infection are three times more likely to contract HIV if exposed. This has a significant impact on the global spread of HIV, as women are more vulnerable to both HIV and HSV II. As a result, the high prevalence of the herpes simplex virus is expected to drive market growth.

Data Bridge Market Research analyses that the HSV1 treatment market which is USD 537.32 million in 2022, is expected to reach USD 1378.65 million by 2030, at a CAGR of 12.5% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

U.S. HSV1 Treatment Market Scope and Segmentation  

​​​​​​​

Market Definition

HSV is a contagious infection that spreads through saliva, sperm, and vaginal secretions and causes painful blisters or ulcers. Physical examinations, fluid sampling, and blood tests are commonly used to diagnose it. Antiviral medications, such as famciclovir, acyclovir, and valacyclovir, are currently the most effective treatment options for patients. These medications can be given orally or intravenously (IV) to help relieve symptoms, reduce the frequency and severity of outbreaks, and prevent virus transmission.

U.S. HSV1 Treatment Market Dynamics

Drivers

• Rising health expenditures

Rising health expenditures, as well as government support to meet the growing demand for effective therapeutics, are encouraging companies to develop novel and innovative medicines. For instance, in June 2021, Innovative Molecules GmbH, a Munich-based drug development company, announced positive results in multiple HSV animal models of its novel drug candidate, IM-250, a second-generation helicase-primase inhibitor of HSV-1 and HSV-2. The company received $23.8 million in series A equity funding led by Life Sciences Partners and plans to begin Phase 1 clinical trials of IM-250 in late 2022 or early 2023.

Opportunities

• Increasing prevalence of Herpes simplex virus-1

The increasing prevalence of Herpes simplex virus-1 encephalitis (HSE), a rare neurological disorder caused by the virus, is expected to drive segment growth. According to the National Organization for Rare Disorders (NORD), HSE affects both men and women equally and usually manifests itself in early childhood or adulthood. In the United States, the disorder accounts for 10% of all reported cases of encephalitis and nearly 2,000 reported cases of acute encephalitis.

Restraints/Challenges

• High cost

HSL, HSV, and related spaces are adequate for selecting a single colour, they ignore much of the complexities of colour appearance. They essentially trade off perceptual relevance for computation speed, dating back to a time in computing history (high-end graphics workstations in the 1970s or mid-1990s consumer desktops) when more sophisticated models would have been too computationally expensive.

Furthermore, Patent expiry and continuous mutation in the virus lead to new strain to restrain market growth in the forecast period.  

This HSV1 treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the HSV1 treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2020, Bausch Health Companies Inc. launched a new telemedicine platform on www.dermatology.com in the United States. This website enables patients to consult with a healthcare professional in order to obtain a prescription on-demand for dermatology products such as Aldara and Solodyn. Aldara is an imiquimod cream used to treat HSV1. This website launch aided the company in attracting patients' attention and raising their awareness of major HSV1 treatment products.
• In 2019, Dr. Reddy's Laboratories Ltd. relaunched Zenatane (Isotretinoin Capsules, USP) for HSV1 treatment. This product launch aided the company in expanding its HSV1 treatment product portfolio.

U.S. HSV1 Treatment Market Scope

The HSV1 treatment market is segmented on the basis of type, occurrence, treatment, route of administration, population type, gender, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Cold Sores
• Genital Herpes

 Occurrence

• Primary Herpes
• Recurrent Herpes

Treatment

• Drugs
• Vaccines

 Route of Administration

• Oral
• Topical
• Parenteral

 Population Type

• Neonates
• Paediatrics
• Adults

 Gender

• Male
• Female

End User

• Hospitals
• Specialty Clinics
• Home Healthcare
• Others

 Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The HSV1 treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for HSV1 treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the HSV1 treatment market. The data is available for historic period 2011-2021.

Competitive Landscape and HSV1 Treatment Market Share Analysis

The HSV1 treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to HSV1 treatment market.

Some of the major players operating in the HSV1 treatment market are:

• Abbott (U.S.)
• Abcam plc. (U.K.)
• BIOMÉRIEUX (France)
• Thermo Fisher Scientific, Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• DiaSorin S.p.A. (Italy)
• Quidel Corporation (U.S.)
• Luminex Corporation (U.S.)
• Merck KGaA (Germany)
• QIAGEN (Germany)
• Norgen Biotek Corp. (Canada)
• Hologic Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Meridian Bioscience, Inc. (U.S.)
• Teco Diagnostics (U.S.)
• GSK plc. (U.K.)
• Agenus Inc. (U.S.)
• Maruho Co., Ltd. (Japan)
• Sanofi (France)

SKU-55297